Lotus Eye Hospital And Institute Ltd (IN:LOTUSEYE)
:LOTUSEYE
Want to see IN:LOTUSEYE full AI Analyst Report?
LOTUSEYE Stock Chart & Stats
₹118.10
-₹0.92(-1.30%)
At close: 4:00 PM EST
₹118.10
-₹0.92(-1.30%)
Day’s Range― - ―
52-Week Range₹68.00 - ₹147.60
Previous CloseN/A
Volume15.88K
Average Volume (3M)2.23K
Market Cap
₹2.88B
Enterprise Value₹3.03B
Total Cash (Recent Filing)₹32.49M
Total Debt (Recent Filing)₹47.99M
Price to Earnings (P/E)3705.8
Beta0.92
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.33
Shares Outstanding20,796,330
10 Day Avg. Volume4,541
30 Day Avg. Volume2,230
Financial Highlights & Ratios
PEG Ratio-27.83
Price to Book (P/B)3.28
Price to Sales (P/S)3.68
P/FCF Ratio-18.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent revenue growth (~6.8% FY2026 vs FY2025) indicates sustained demand for core ophthalmology services. Over a 2–6 month horizon this supports stable patient volumes and utilization, underpins operating scale, and provides a foundation for possible margin recovery if cost controls follow.
Focused Ophthalmology Business ModelA specialized ophthalmology platform with diversified patient-pay streams (consultations, diagnostics, surgical revenue, pharmacy/consumables, optical sales) creates durable, repeatable revenue and cross-sell opportunities. Specialization supports clinical reputation, operational efficiencies and patient retention over the medium term.
Equity-supported Balance SheetThe balance sheet is largely equity-backed (equity ~601M vs debt ~158M; D/E ~0.26), giving moderate financial headroom. That equity buffer supports capacity to fund operations or selective investments and absorb shocks, offering a degree of resilience while profitability and cash flow trends improve.
Bears Say
Margin DeteriorationOperating margin slipping to ~-0.7% and net margin compressing to ~0.15% from prior ~1.5% materially reduces internal earnings capacity. Sustained margin weakness undermines the ability to self-fund growth, increases sensitivity to cost pressures, and raises the bar for achieving durable profitability.
Deeply Negative Free Cash FlowFree cash flow swinging to ~-106M in FY2026 after prior negative FCF signals heavy reinvestment or working-capital strain. Persistent negative FCF forces reliance on external funding, constrains discretionary investment, and elevates liquidity and refinancing risk absent a clear path to cash generation.
Rapidly Rising LeverageLeverage rising quickly from ~0.06 to ~0.26 in one year increases interest and refinancing exposure. With weak margins and negative FCF, higher debt magnifies financial vulnerability, constrains strategic flexibility and raises the risk profile if operating performance does not rebound.
Lotus Eye Hospital And Institute Ltd News
LOTUSEYE FAQ
What was Lotus Eye Hospital And Institute Ltd’s price range in the past 12 months?
Lotus Eye Hospital And Institute Ltd lowest stock price was ₹68.00 and its highest was ₹147.60 in the past 12 months.
What is Lotus Eye Hospital And Institute Ltd’s market cap?
Lotus Eye Hospital And Institute Ltd’s market cap is ₹2.88B.
When is Lotus Eye Hospital And Institute Ltd’s upcoming earnings report date?
Lotus Eye Hospital And Institute Ltd’s upcoming earnings report date is Aug 17, 2026 which is in 61 days.
How were Lotus Eye Hospital And Institute Ltd’s earnings last quarter?
Lotus Eye Hospital And Institute Ltd released its earnings results on May 26, 2026. The company reported -₹0.15 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.15.
Is Lotus Eye Hospital And Institute Ltd overvalued?
According to Wall Street analysts Lotus Eye Hospital And Institute Ltd’s price is currently Overvalued.
Does Lotus Eye Hospital And Institute Ltd pay dividends?
Lotus Eye Hospital And Institute Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Lotus Eye Hospital And Institute Ltd dividends here
What is Lotus Eye Hospital And Institute Ltd’s EPS estimate?
Lotus Eye Hospital And Institute Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lotus Eye Hospital And Institute Ltd have?
Lotus Eye Hospital And Institute Ltd has 20,796,330 shares outstanding.
What happened to Lotus Eye Hospital And Institute Ltd’s price movement after its last earnings report?
Lotus Eye Hospital And Institute Ltd reported an EPS of -₹0.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.69%.
Which hedge fund is a major shareholder of Lotus Eye Hospital And Institute Ltd?
Currently, no hedge funds are holding shares in IN:LOTUSEYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lotus Eye Hospital And Institute Ltd
Lotus Eye Hospital and Institute Limited is an Indian ophthalmic healthcare provider delivering a broad spectrum of eye care services nationwide. Its comprehensive offerings include specialized treatments for refractive errors, conditions impacting the retina and uvea, corneal diseases, glaucoma management, and pediatric eye care, including squint correction. The hospital also addresses computer vision syndrome, performs orbit and oculoplasty procedures, offers neuro-ophthalmology, and provides binocular vision services. In addition to clinical services, the company supplies cataract and intraocular lenses and operates a dedicated eye bank. Committed to medical education, it conducts ophthalmic fellowship training in areas such as cornea, glaucoma, retina, and anterior segments, alongside DNB teaching and training programs. Founded in 1997, the company changed its name from Lotus Eye Care Hospital Limited to its present Lotus Eye Hospital and Institute Limited in April 2013. Its base of operations is in Coimbatore, India.
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―